Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 4/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 2/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bendamustine SCHEMBL29394147 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL9950832 | 1.00 | HDAC6 (1.00) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15523734 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL12497247 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL18843 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL29352819 | 0.99 | HDAC6 (0.98) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL15436003 | 0.98 | HDAC6 (0.96) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL118499 | 0.98 | HDAC6 (0.96) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| SCHEMBL16772708 | 0.97 | HDAC6 (0.94) | HDAC6HDAC1HDAC3HDAC4HDAC2 | |
| Bendamustine SCHEMBL23909358 | 0.96 | HDAC6 (0.92) | HDAC6HDAC1HDAC3HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 35584 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260139071-A1 | Subcutaneous Formulations Of Anti-CD38 Antibodies And Their Uses | JANSSEN BIOTECH INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107377-A1 | PHARMACOLOGICAL RE-ACTIVATION OF MUTANT PVHL | KARANICOLAS JOHN (US) | 2026-05-21 | — | — | WO | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-12630603-B2 | Chimeric antigen receptor T cell therapy | KITE PHARMA, INC. (US) | 2026-05-19 | — | — | US | claimed |
| CN-122055366-A | GCN2 and PERK kinase modulators and methods of use thereof | 德西费拉制药有限责任公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026102456-A1 | METHODS OF TREATING CANCER BY ADMINISTERING BISPECIFIC CD19/CD20 CAR T CELLS | LYELL IMMUNOPHARMA, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| EP-1444989-A1 | Sensitizing cells for apoptosis by selectively blocking cytokines | Stassi, Giorgio, Dr. (IT) | 2004-08-11 | — | — | EP | claimed |
| US-20040152672-A1 | Indole compounds useful for the treatment of cancer | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-08-05 | — | — | US | claimed |
| EP-1435877-A1 | COATING OF STENTS FOR PREVENTING RESTENOSIS | Hemoteq GmbH (DE) | 2004-07-14 | — | — | EP | claimed |
| US-20040072889-A1 | Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia | PHARMACIA CORPORATION | 2004-04-15 | — | — | US | claimed |
| WO-2003094990-A1 | COMPOUNDS AND METHOD FOR COATING SURFACES IN A HAEMOCOMPATIBLE MANNER | HEMOTEQ GMBH (DE) | 2003-11-20 | — | — | WO | claimed |
| WO-2003086470-A2 | SMAC-PEPTIDES AS THERAPEUTICS AGAINST CANCER AND AUTOIMMUNE DISEASES | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2003-10-23 | — | — | WO | claimed |
| EP-1354952-A1 | Smac-peptides as therapeutics against cancer and autoimmune diseases | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2003-10-22 | — | — | EP | claimed |
| EP-1354953-A1 | Smac-peptides as therapeutics against cancer and autoimmune diseases | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2003-10-22 | — | — | EP | claimed |
| WO-2003081238-A2 | CYTOCAPACITY TEST | Ludwig Maximilians Universität (DE) | 2003-10-02 | — | — | WO | claimed |
| WO-2003034944-A1 | COATING OF STENTS FOR PREVENTING RESTENOSIS | HEMOTEQ GMBH (DE) | 2003-05-01 | — | — | WO | claimed |